Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

A study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS.
News ReleasesAugust 24, 2022

News on HVTN

Read MORE
A promising HIV vaccine candidate gets a little help New strategy stirs a robust response from T cells tracked by McElrath lab May 24, 2023
Year in Pictures: 2022 A look back at the year through compelling images December 12, 2022
Could a 100-year-old TB vaccine help scientists find a better one? Harmless vaccine BCG is made of living bacteria; in tests might serve as a proxy for deadly tuberculosis December 12, 2022
Dr. Larry Corey receives Alexander Fleming Award Virologist honored by peers for his lifetime achievements against infectious diseases October 21, 2022